{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:54:18Z","timestamp":1774594458205,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.taap.2023.116459","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T20:32:33Z","timestamp":1678480353000},"page":"116459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Designer benzodiazepine rat pharmacokinetics: A comparison of alprazolam, flualprazolam and flubromazolam"],"prefix":"10.1016","volume":"465","author":[{"given":"Jeremy R.","family":"Canfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Kisor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon E.","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.taap.2023.116459_bb0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/ADM.0000000000000350","article-title":"A review of alprazolam use, misuse, and withdrawal","volume":"12","author":"Ait-Daoud","year":"2018","journal-title":"J. Addict. Med."},{"issue":"2","key":"10.1016\/j.taap.2023.116459_bb0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/pr.117.014381","article-title":"Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery","volume":"70","author":"Atkin","year":"2018","journal-title":"Pharmacol. Rev."},{"issue":"5","key":"10.1016\/j.taap.2023.116459_bb0015","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cbic.200301023","article-title":"Fluorine in medicinal chemistry","volume":"5","author":"B\u00f6hm","year":"2004","journal-title":"ChemBioChem"},{"issue":"3","key":"10.1016\/j.taap.2023.116459_bb0020","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/neurolint14030053","article-title":"Novel designer benzodiazepines: comprehensive review of evolving clinical and adverse effects","volume":"14","author":"Edinoff","year":"2022","journal-title":"Neurol. Int."},{"issue":"9","key":"10.1016\/j.taap.2023.116459_bb0025","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/0269881119901096","article-title":"Designer benzodiazepines\u2019 pharmacological effects and potencies: how to find the information","volume":"34","author":"El Balkhi","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.taap.2023.116459_bb0030","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11419-021-00591-w","article-title":"A case of fatal multidrug intoxication involving flualprazolam: distribution in body fluids and solid tissues","volume":"40","author":"Giorgetti","year":"2022","journal-title":"Forensic Toxicol."},{"issue":"6","key":"10.1016\/j.taap.2023.116459_bb0035","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003088-199324060-00003","article-title":"Clinical pharmacokinetics of alprazolam","volume":"24","author":"Greenblatt","year":"1993","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.taap.2023.116459_bb0040","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/cpdd.667","article-title":"Designer benzodiazepines: a review of published data and public health significance","volume":"8","author":"Greenblatt","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"6","key":"10.1016\/j.taap.2023.116459_bb0045","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/acsmedchemlett.8b00018","article-title":"Strategy for extending half-life in drug design and its significance","volume":"9","author":"Gunaydin","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"15","key":"10.1016\/j.taap.2023.116459_bb0050","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1021\/jm800219f","article-title":"The many roles for fluorine in medicinal chemistry","volume":"51","author":"Hagmann","year":"2008","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.taap.2023.116459_bb0055","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/dta.2203","article-title":"Flubromazolam - basic pharmacokinetic evaluation of a highly potent designer benzodiazepine","volume":"10","author":"Huppertz","year":"2017","journal-title":"Drug Test. Anal."},{"issue":"5846","key":"10.1016\/j.taap.2023.116459_bb0060","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1126\/science.1131943","article-title":"Fluorine in pharmaceuticals: looking beyond intuition","volume":"317","author":"Klaus","year":"2007","journal-title":"Sci."},{"issue":"2","key":"10.1016\/j.taap.2023.116459_bb0065","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/dta.2349","article-title":"The emergence of new psychoactive substance (NPS) benzodiazepines: a review","volume":"10","author":"Manchester","year":"2018","journal-title":"Drug Test. Anal."},{"issue":"8","key":"10.1016\/j.taap.2023.116459_bb0070","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/dta.2146","article-title":"In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples","volume":"9","author":"Noble","year":"2017","journal-title":"Drug Test. Anal."},{"issue":"9","key":"10.1016\/j.taap.2023.116459_bb0075","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2174\/1570159X18666200110121333","article-title":"\u2018New\/designer benzodiazepines\u2019: an analysis of the literature and psychonauts\u2019 trip reports","volume":"18","author":"Orsolini","year":"2020","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.taap.2023.116459_bb0080","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0022-3565(25)20232-4","article-title":"The effects of alprazolam on corticotropin-releasing factor neurons in the brain: acute time course, chronic treatment and abrupt withdrawal","volume":"258","author":"Owens","year":"1991","journal-title":"J Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.taap.2023.116459_bb0085","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/sj.tpj.6500115","article-title":"Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacologically active metabolite","volume":"2","author":"Pai","year":"2002","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.taap.2023.116459_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045125320967197","article-title":"New psychoactive substances: a review and updates","volume":"10","author":"Shafi","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.taap.2023.116459_bb0095","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14756360701425014","article-title":"The role of fluorine in medicinal chemistry","volume":"22","author":"Shah","year":"2007","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.taap.2023.116459_bb0100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s002130000469","article-title":"A comparison of plasma alprazolam concentrations following different routes of chronic administration in the Sprague-Dawley rat: implications for psychotropic drug research","volume":"151","author":"Skelton","year":"2000","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.taap.2023.116459_bb0105","series-title":"National Forensic Laboratory Information System: NIFLIS-Drug 2019 Annual Report","author":"U.S. Drug Enforcement Administration, Diversion Control Division","year":"2020"},{"key":"10.1016\/j.taap.2023.116459_bb0110","series-title":"National Forensic Laboratory Information System: NIFLIS-Drug 2020 Annual Report","author":"U.S. Drug Enforcement Administration, Diversion Control Division","year":"2021"},{"key":"10.1016\/j.taap.2023.116459_bb0115","series-title":"National Forensic Laboratory Information System: NIFLIS-Drug 2021 Midyear Report","author":"U.S. Drug Enforcement Administration, Diversion Control Division","year":"2022"},{"issue":"9","key":"10.1016\/j.taap.2023.116459_bb0120","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/jat\/bkaa161","article-title":"Flubromazolam-derived designer benzodiazepines: Toxicokinetics and analytical toxicology of Clobromazolam and Bromazolam","volume":"45","author":"Wagmann","year":"2020","journal-title":"J. Anal. Toxicol."},{"issue":"6","key":"10.1016\/j.taap.2023.116459_bb0125","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/jat\/bkaa019","article-title":"Toxicokinetics and analytical toxicology of flualprazolam: metabolic fate, isozyme mapping, human plasma concentration and main urinary excretion products","volume":"44","author":"Wagmann","year":"2020","journal-title":"J. Anal. Toxicol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:01:43Z","timestamp":1758574903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X23000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":25,"alternative-id":["S0041008X23000972"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2023.116459","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Designer benzodiazepine rat pharmacokinetics: A comparison of alprazolam, flualprazolam and flubromazolam","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2023.116459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116459"}}